Key facts
- This page summarizes Muhammad Al-Hajj's Form 4 filing for IO Biotech, Inc. (IOBT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Mar 2023, 16:40.
Muhammad Al-Hajj - 20 Mar 2023 Form 4 Insider Report for IO Biotech, Inc. (IOBT)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- IOBT
- Reported as of
- 20 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Mar 2023, 16:40:14 UTC
- Prior SEC filing
- 04 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Burkavage, Attorney-in-Fact for Muhammad Al-Hajj
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Muhammad Al-Hajj filed Form 4 for IO Biotech, Inc. (IOBT) on 22 Mar 2023.
Change
- Previous filing in this sequence was filed on 04 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IOBT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 20 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $1.98
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control.